BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with ER+ advanced or MBC, & in a PIK3CA mutant sub-population March 12, 2019